Item 5.07. Submission of Matters to a Vote of Security Holders.




In order to support the health and well-being of HCA Healthcare, Inc.'s (the
"Company's") stockholders, employees and community due to the impact of the
COVID-19 pandemic, the Company held its Annual Meeting of Stockholders (the
"Annual Meeting") on April 28, 2021 in a virtual meeting format only, via
webcast. At the Annual Meeting, a total of 308,314,735 shares of our common
stock, out of a total of 336,936,865 shares of common stock outstanding and
entitled to vote, were represented in person or by proxy. Voting results from
the Annual Meeting were as follows:

1. The following nine director nominees were elected to the Company's Board of
Directors for a one-year term, or until such director's respective successor is
duly elected and qualified or such director's earlier death, resignation or
removal, as follows:



                                             For            Against        Abstentions       Broker Non-Votes
Thomas F. Frist III                       285,519,060        6,020,841          630,805             16,144,029
Samuel N. Hazen                           290,889,075          651,378          630,253             16,144,029
Meg G. Crofton                            290,867,743          665,357          637,606             16,144,029
Robert J. Dennis                          286,178,869        5,349,768          642,069             16,144,029
Nancy-Ann DeParle                         284,708,899        6,825,150          636,657             16,144,029
William R. Frist                          290,180,394        1,336,162          654,150             16,144,029
Charles O. Holliday, Jr.                  269,231,973       21,611,847        1,326,886             16,144,029
Michael W. Michelson                      290,108,255        1,400,530          661,921             16,144,029
Wayne J. Riley, M.D.                      286,377,487        5,157,310          635,909             16,144,029


2. The selection of Ernst & Young LLP as the Company's independent registered
public accounting firm for the year ending December 31, 2021 was ratified as
follows:



    For        Against     Abstentions   Broker Non-Votes
289,047,637   18,646,258     620,840            0

3. The adoption of a non-binding advisory resolution on the Company's named executive officer compensation as described in the Company's 2021 proxy statement was approved as follows:





    For        Against     Abstentions   Broker Non-Votes
280,813,046   10,403,853     953,807        16,144,029


4. The stockholder proposal regarding stockholders' ability to act by written
consent as described in the Company's 2021 proxy statement was not approved as
follows:



   For         Against     Abstentions   Broker Non-Votes
65,388,322   225,643,421    1,138,963       16,144,029

5. The stockholder proposal requesting a report on the feasibility of increasing the impact of quality metrics on executive compensation as described in the Company's 2021 proxy statement was not approved as follows:





   For         Against     Abstentions   Broker Non-Votes
28,463,199   261,741,413    1,966,094       16,144,029

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits:



  Exhibit
    No.                                     Description

Exhibit 104     Cover Page Interactive Data File (embedded within the Inline XBRL
                document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses